Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VALERGEN-DP
- Development stage
- Unknown
- Lead developer
- BioCen
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Sublingual
01
Overview
VALERGEN-DP is an allergen-specific immunotherapy (AIT) product developed and produced by the Centro Nacional de Biopreparados (BioCen) in Cuba. It is a standardized allergenic extract derived from cultured *Dermatophagoides pteronyssinus* (house dust mite), standardized in Biological Units (UB). The vaccine is indicated for the treatment of allergic diseases, specifically asthma and rhinitis, in patients sensitized to this mite species. It functions by administering progressively increasing doses of the allergen to induce immune tolerance, thereby reducing clinical symptoms and the need for rescue medication. VALERGEN-DP is available in both subcutaneous (injectable) and sublingual formulations and has received regulatory approval from the Cuban authority CECMED.
- Brand names
- VALERGEN-DP
- Other names
- Dermatophagoides pteronyssinus allergen vaccineVALERGEN DP
02
Targets
HDM-specific IgE (House dust mite-specific immunoglobulin E)High-affinity immunoglobulin epsilon receptor-bound Immunoglobulin E complex
Beyond the preview
Go deeper on VALERGEN-DP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VALERGEN-DP.